The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
“Salvage” neoadjuvant bevacizumab in newly diagnosed glioblastoma multiforme (GBM).
Ciprian Barlog
No relevant relationships to disclose
Emeline Tabouret
No relevant relationships to disclose
Marc Sanson
Honoraria - Roche
Ahmed Idbaih
Honoraria - Roche
Caroline Houillier
No relevant relationships to disclose
Florence Laigle-Donadey
No relevant relationships to disclose
Agusti Alentorn
No relevant relationships to disclose